Insmed Stock Price

-1.03 (-2.83%)
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Insmed Inc INSM NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-1.03 -2.83% 35.195 16:02:00
Close Price Low Price High Price Open Price Previous Close
35.20 34.39 36.10 35.75 36.22
Bid Price Ask Price Spread News
34.49 47.00 12.51 1 2
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
9,961 740,607 $ 35.27 $ 26,121,147 867,426 12.09 - 39.39
Last Trade Time Type Quantity Stock Price Currency
16:02:38 98 $ 35.195 USD

Insmed Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 3.57B 101.48M 75.68M $ 136.47M $ - -3.03 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Insmed News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical INSM Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week38.6039.3934.3936.73834,572-3.41-8.82%
1 Month32.7539.3931.6035.50723,5392.457.47%
3 Months26.9939.3926.2831.88831,0268.2130.4%
6 Months22.9139.3920.8628.30937,89012.2953.62%
1 Year18.4239.3912.0924.951,065,44216.7891.07%
3 Years27.2039.3911.3123.76964,5918.0029.39%
5 Years19.4139.399.0222.54773,08415.7981.32%

Insmed Description

Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.